Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Free Report) insider Hanlin Gao sold 939 shares of the company’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $19.91, for a total transaction of $18,695.49. Following the transaction, the insider owned 987,790 shares of the company’s stock, valued at approximately $19,666,898.90. The trade was a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Hanlin Gao also recently made the following trade(s):
- On Tuesday, June 2nd, Hanlin Gao sold 1,688 shares of Fulgent Genetics stock. The stock was sold at an average price of $17.89, for a total transaction of $30,198.32.
Fulgent Genetics Stock Down 1.7%
NASDAQ FLGT traded down $0.34 during midday trading on Friday, hitting $19.61. The company had a trading volume of 192,538 shares, compared to its average volume of 431,774. The firm has a fifty day simple moving average of $19.59 and a two-hundred day simple moving average of $18.14. Fulgent Genetics, Inc. has a fifty-two week low of $13.46 and a fifty-two week high of $31.04. The stock has a market cap of $539.57 million, a price-to-earnings ratio of -6.95 and a beta of 0.90.
Analyst Ratings Changes
Several equities analysts have commented on the company. Weiss Ratings raised Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Wall Street Zen lowered Fulgent Genetics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Finally, Piper Sandler boosted their price objective on Fulgent Genetics from $15.00 to $19.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $27.50.
Check Out Our Latest Research Report on FLGT
Hedge Funds Weigh In On Fulgent Genetics
A number of hedge funds and other institutional investors have recently made changes to their positions in FLGT. BlackRock Inc. acquired a new stake in shares of Fulgent Genetics during the 2nd quarter valued at about $46,922,000. Northwestern Mutual Wealth Management Co. raised its position in Fulgent Genetics by 2,984,354.9% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,522,072 shares of the company’s stock worth $39,985,000 after purchasing an additional 1,522,021 shares in the last quarter. RTW Investments LP acquired a new position in Fulgent Genetics in the fourth quarter worth about $18,521,000. JPMorgan Chase & Co. raised its position in Fulgent Genetics by 767.0% in the third quarter. JPMorgan Chase & Co. now owns 299,014 shares of the company’s stock worth $6,758,000 after purchasing an additional 264,524 shares in the last quarter. Finally, Medina Value Partners LLC bought a new position in Fulgent Genetics during the second quarter worth about $3,961,612. 48.06% of the stock is owned by institutional investors.
Fulgent Genetics Company Profile
Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.
Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.
Featured Articles
- Five stocks we like better than Fulgent Genetics
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
